Summary
Semax is stimulating and BDNF-upregulating. Selank is calming and anxiolytic. Both are Russian-developed cognitive peptides with different profiles. This comparison explains when each is studied and why they are sometimes combined.
The Core Difference
Semax stimulates. It upregulates BDNF (brain-derived neurotrophic factor), increases dopamine turnover, and produces a cognitively activating effect in research settings.
Selank calms. It modulates GABA-A receptors and serotonin pathways, producing anxiolytic effects without sedation.
They address different aspects of cognitive performance — and this is why they are sometimes combined.
Quick Comparison
| Semax | Selank | |
|---|---|---|
| Derived from | ACTH(4-10) fragment | Tuftsin analogue |
| Primary mechanism | BDNF upregulation, dopamine/serotonin modulation | GABAergic, serotonin modulation, anxiolytic |
| Cognitive effect profile | Stimulating, focus-enhancing, neuroprotective | Calming, anxiety-reducing, mildly focus-supporting |
| Developed by | Institute of Molecular Genetics, Russia | Institute of Molecular Genetics, Russia |
| Russian approval status | Approved as a nootropic in Russia | Approved as an anxiolytic in Russia |
| Common administration | Intranasal or subcutaneous | Intranasal or subcutaneous |
How Semax Works
Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment (a portion of adrenocorticotropic hormone). Unlike ACTH itself, Semax has no hormonal activity on the adrenal glands — the relevant portion is the fragment that modulates brain activity.
Its primary characterised mechanism is BDNF upregulation: Semax significantly increases the expression of BDNF and its receptor TrkB in the hippocampus — a region central to memory, learning, and mood regulation. BDNF supports neuronal survival, synaptic plasticity, and the formation of new connections.
Semax also influences:
- Dopamine and serotonin turnover in several brain regions
- VEGF (vascular endothelial growth factor) — relevant to cerebral blood flow
- Neuroprotective mechanisms — studied in the context of stroke recovery and neurodegeneration in animal models
The user experience of Semax in research contexts is often described as mentally energising — improved working memory, sharper attention, and faster processing. At higher doses, some researchers note slight anxiety or overstimulation.
How Selank Works
Selank is a synthetic analogue of tuftsin — a naturally occurring tetrapeptide with immune-modulating properties. The synthetic version adds a stabilising sequence that extends its half-life.
Its primary mechanism involves the GABA-A receptor system and serotonin pathways:
- Modulates GABA-A receptor sensitivity, producing anxiolytic effects
- Increases serotonin turnover in certain brain regions
- Shows enkephalin-like (opioid receptor) activity in some studies — possibly contributing to its mood-stabilising profile
Selank's anxiolytic effect is notably different from benzodiazepines — it does not cause sedation or cognitive impairment at standard research doses, and no dependence or withdrawal has been documented in animal studies. This profile is what distinguishes it from conventional anxiolytics.
Immunomodulatory effects have also been documented — Selank appears to influence immune cell activity, though the clinical significance in healthy subjects is unclear.
When Each Is Relevant
Semax is studied for:
- Acute cognitive performance enhancement (focus, memory, processing speed)
- Post-stroke cognitive recovery (animal and some clinical research)
- Depression and mood (BDNF pathway)
- Neuroprotection
Selank is studied for:
- Anxiety reduction without sedation
- Anxiety-related cognitive impairment
- Stress resilience
- Mild mood stabilisation
Combined, they may address:
- High cognitive demand situations where anxiety limits performance
- Protocols where cognitive stimulation is desired but overstimulation is a risk
Evidence Context
Both compounds were developed and studied primarily within the Russian research system. While they are approved medications in Russia for cognitive and anxiolytic indications respectively, their evidence base in Western peer-reviewed literature is limited. Most publications are from Russian institutions, and large randomised controlled trials meeting current Western standards have not been conducted.
This does not invalidate the research — but it means extrapolation to a broader population requires appropriate caution.
Related Topics
Safety & Regulatory Note
Both Semax and Selank are research peptides developed in Russia, where they have been studied in clinical contexts. They are not approved as medications in most Western countries and are supplied for research use only.
References
- 1.Agapova TY, et al. (2007). Effects of semax on the expression of BDNF and its receptor in the rat hippocampus. Bulletin of Experimental Biology and Medicine, 143(5), 601–604.
- 2.Zozulya AA, et al. (2001). The characterization and possible functional significance of the opiate-like properties of Selank. Bulletin of Experimental Biology and Medicine, 131(4), 315–318.
- 3.Eremin KO, et al. (2005). Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1028(1), 82–88.
